Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma

Frontiers in Immunology(2022)10.3389/fimmu.2022.892250Source: DataRank Database

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma is a research paper published in Frontiers in Immunology (2022). On theSindex it has a DataRank of 0. It has been cited 89 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access89 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 7.11)OA: goldTopics (49)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Won Jin Ho ORCID,Mark Yarchoan ORCID,Aleksander S. Popel ORCID,Haoyang Mi ORCID

Live enrichment

PubMed:35634309 PMC:PMC9136005 OpenAlex:https://openalex.org/W4280650826

NCI NIH HHS

Grant: U01 CA212007

Emerson Collective

Grant: 640183

NCI NIH HHS

Grant: P50 CA062924

NCI NIH HHS

Grant: R01 CA138264

National Institutes of Health

Grant: U01CA212007 , R01CA138264

National Institutes of Health

Grant: 5U01CA212007-03

Integrating bioinformatics into multiscale models for hepatocellular carcinoma

National Institutes of Health

Grant: 5P50CA062924-25

SPORE in Gastrointestinal Cancers

National Institutes of Health

Grant: 5R01CA138264-13

Predictive experiment-based multiscale models of the tumor immune microenvironment and immunotherapy in breast cancer

Exelixis

Passano Foundation

Bristol-Myers Squibb

FWCI

7.11

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.3389/fimmu.2022.892250

publisherhttps://doi.org/10.3389/fimmu.2022.892250

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35634309

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9136005

repositoryhttps://doaj.org/article/d81a43d30e3e4602bc9a1c0180cf2e12

Fields of Study

Single-cell and spatial transcriptomicsCancer Immunotherapy and BiomarkersImmune cells in cancer0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

NivolumabAnilidesCarcinoma, HepatocellularHumansLiver NeoplasmsPyridinesCD8-Positive T-LymphocytesVascular Endothelial Growth Factor ATumor MicroenvironmentB7-H1 AntigenSpatial Analysis

Keywords

Tumor microenvironmentCabozantinibCancer researchNivolumabMass cytometryTissue microarrayMedicineCD8Stromal cellImmune systemCancerImmunotherapyBiologyImmunologyInternal medicinePhenotypeHepatocellular carcinomaBiomarkersystems biologycomputational biologyTumor-immune Microenvironments (Time)Vascular Endothelial Growth Factor ASpatial AnalysisCarcinoma, HepatocellularPyridinesLiver NeoplasmsRC581-607CD8-Positive T-LymphocytesB7-H1 AntigenHumansAnilidesImmunologic diseases. Allergy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Reduced inequalities

Additional file 1 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722287.v1figshare

Additional file 1 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722287figshare

Additional file 2 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722290.v1figshare

Additional file 2 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722290figshare

Additional file 3 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722293.v1figshare

Additional file 3 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722293figshare

Additional file 4 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722299figshare

Additional file 4 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722299.v1figshare

Additional file 5 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722302.v1figshare

Additional file 5 of Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma

10.6084/m9.figshare.23722302figshare

Additional file 1 of Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response

10.6084/m9.figshare.25097346.v1figshare

Additional file 1 of Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response

10.6084/m9.figshare.25097346figshare

Additional file 5 of Comprehensive analysis identifies CLEC1B as a potential prognostic biomarker in hepatocellular carcinoma

10.6084/m9.figshare.26596760.v1figshare

Additional file 5 of Comprehensive analysis identifies CLEC1B as a potential prognostic biomarker in hepatocellular carcinoma

10.6084/m9.figshare.26596760figshare

Additional file 1 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

10.6084/m9.figshare.26618014.v1figshare

Additional file 1 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

10.6084/m9.figshare.26618014figshare

Additional file 3 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

10.6084/m9.figshare.26618020.v1figshare

Additional file 3 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

10.6084/m9.figshare.26618020figshare

Additional file 4 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

10.6084/m9.figshare.26618023.v1figshare

Additional file 4 of Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

10.6084/m9.figshare.26618023figshare